Post-Exposure Prophylaxis (PEP) for HIV: Timing, Regimens, and Evidence

1. Introduction: Definition and Rationale

Post-exposure prophylaxis (PEP) for HIV is the short-term use of antiretroviral drugs to prevent infection after a potential exposure to the virus. PEP is a medical emergency: it is a 28-day course of three antiretroviral drugs, begun as soon as possible after exposure and no later than 72 hours afterward, with the greatest benefit when started within 24 to 36 hours. It is used after occupational exposures — most classically a needlestick or other percutaneous injury involving a healthcare worker — and after non-occupational exposures, such as condomless sexual contact or sharing of injection equipment.

The conceptual foundation of PEP is straightforward: HIV infection is not instantaneous. After the virus crosses a mucosal or cutaneous barrier, there is a period of hours to a few days during which replication is local and limited, before the virus spreads to regional lymph nodes and establishes a systemic, self-sustaining infection and a persistent viral reservoir. If sufficiently potent antiretroviral drugs are present during this early window, they can abort the nascent infection. Once the reservoir is established, however, antiretroviral therapy can suppress but cannot eradicate the virus, and PEP no longer has any rationale.

This article distinguishes the strength of evidence across settings. PEP is unusual in HIV medicine in that the quality of the underlying evidence varies sharply: the occupational setting rests on a well-known case-control study, whereas the non-occupational setting rests largely on biological plausibility, animal models, and observational data rather than randomized trials.

2. Mechanism: Blocking Early Replication

The mechanism of PEP is best understood as interrupting the viral life cycle before it becomes self-sustaining. In the hours after exposure:

• The virus crosses the epithelial barrier and infects the first susceptible cells — dendritic cells, macrophages, and CD4 T cells in the mucosa.
• Local replication proceeds and viral particles drain through lymphatics to the regional lymph nodes, where large numbers of CD4 T cells become infected.
• Within days, virus enters the bloodstream and disseminates, seeding the gut-associated lymphoid tissue and other compartments that form the long-lived latent reservoir.

Antiretrovirals do not kill virus particles or infected cells; they prevent new rounds of infection. A three-drug regimen therefore acts as a wall that stops the exponential amplification of the virus while the initial exposed cells die off naturally, allowing the immune system to clear the small founder population. This is why PEP must be started early and continued long enough (28 days) to cover the period of ongoing exposure risk from any cells that were already infected. Because the drugs act at different steps of the cycle — reverse transcription and integration, for the recommended backbone and integrase inhibitor — the combination is more strong than a single agent.

3. The 72-Hour Window and Why Timing Matters

The 72-hour cutoff is the single most important practical rule. It derives from animal-model data showing that prophylaxis becomes progressively less effective as the interval between exposure and treatment lengthens, and from the biology of early dissemination. In macaque models using simian immunodeficiency virus (SIV) or SHIV, antiretroviral prophylaxis started within hours was highly protective, while delayed initiation reduced or abolished the benefit.

Two practical principles follow:

• Start immediately. Do not wait for the results of baseline tests or for the source person’s HIV status to be confirmed if the exposure is judged to carry risk. If the source is later found to be HIV-negative, PEP can be stopped.
• Within 72 hours, sooner is better. Initiation within 24 to 36 hours is preferred. Beyond 72 hours, PEP is generally not recommended because there is little evidence of benefit; exceptions may be considered case by case, particularly with high-risk exposures, but this falls outside the standard recommendation. **[Marked for verification.]**

4. Occupational PEP: The Evidence Base

The strongest evidence for any form of HIV PEP comes from the occupational setting, specifically healthcare workers exposed to blood or body fluids through needlesticks, cuts, or mucous-membrane contact. The central study was a retrospective case-control study of zidovudine PEP in healthcare workers published by Cardo and colleagues in the New England Journal of Medicine in 1997. Because it would be unethical to randomize healthcare workers to no prophylaxis, the investigators compared healthcare workers who seroconverted after occupational exposure (cases) with those who did not (controls), examining whether they had received zidovudine. The analysis found that zidovudine use was associated with a reduction in the odds of HIV transmission of roughly 81% (adjusted odds ratio approximately 0.19).

This study remains the foundational human evidence that antiretroviral prophylaxis can prevent HIV acquisition after exposure. Its limitations are those of any observational case-control design: potential confounding, reliance on reported exposures, and the fact that it evaluated zidovudine monotherapy, which is no longer used. Nevertheless, the magnitude and consistency of the effect, combined with supporting animal data, justify the use of more potent modern three-drug regimens, which are assumed to be at least as effective. Occupational PEP for a percutaneous exposure from a known HIV-positive source is standard of care in essentially all guidelines.

5. Non-Occupational PEP (nPEP)

Non-occupational PEP (nPEP) is the use of the same 28-day regimen after a sexual exposure or after sharing injection-drug equipment. Its use expanded in the late 1990s and 2000s as guidelines were issued by public-health agencies, including the U.S. CDC and the World Health Organization.

Here the evidence is weaker, and this must be stated plainly. No randomized controlled trial has demonstrated that nPEP prevents HIV acquisition. The recommendation rests on a chain of inference:

• biological plausibility and the established mechanism described above;
• animal-model protection against mucosal SHIV/SIV challenge;
• the occupational case-control evidence, extrapolated to mucosal exposure; and
• observational cohorts and case series, which have generally shown favorable but not statistically conclusive outcomes, and are limited by the fact that many exposed people do not complete the course and many exposures carry very low baseline risk.

Accordingly, nPEP should be described as a recommended intervention supported by moderate-to-indirect evidence rather than a proven one. It is nonetheless widely and justifiably used, because the alternative — doing nothing after a high-risk exposure — carries substantial risk, and the intervention is safe. The strength of the recommendation increases with the risk of the exposure: receptive anal intercourse with a known HIV-positive source not virologically suppressed is a far stronger indication than a single episode of condom-protected contact.

Injection-related exposure is another nPEP indication. Sharing needles or syringes with a person of unknown or positive HIV status carries a transmission risk that, while lower than commonly assumed, is not negligible, and PEP is reasonable where the exposure is substantial.

6. Recommended Regimens

Modern PEP uses a three-drug regimen combining a nucleoside/nucleotide reverse transcriptase inhibitor backbone with an integrase strand transfer inhibitor (INSTI). The most widely recommended regimen is:

• Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) or, where bone or kidney considerations favor it, tenofovir alafenamide/emtricitabine (TAF/FTC), plus
• Dolutegravir (DTG) 50 mg once daily.

Dolutegravir has largely displaced older third agents because it achieves rapid viral suppression, has a favorable tolerability profile, and is potent against most resistant viruses. Alternatives include raltegravir (RAL) 400 mg twice daily and, in some settings, a ritonavir- or cobicistat-boosted protease inhibitor such as darunavir. The choice depends on local guidelines, availability, drug interactions, pregnancy status, and the source person’s known resistance profile.

Because TDF, TAF, and FTC are active against hepatitis B virus, the same backbone provides incidental HBV protection, which is relevant when the exposure source or the exposed person has HBV. Regimens should be adjusted for renal function, and TDF is generally avoided when renal impairment is present.

7. Baseline Assessment, Monitoring, and Follow-up Testing

Before or at the time of starting PEP, a baseline evaluation is performed. Importantly, these tests should not delay initiation when the exposure warrants PEP.

• HIV testing at baseline, to identify anyone who is already infected (PEP is not a treatment for established infection and would risk mono/dual-therapy resistance).
• Hepatitis B and C testing, and liver enzymes where relevant.
• Renal function (creatinine, estimated glomerular filtration rate), because of tenofovir.
• Pregnancy testing and STI screening as appropriate.
• Assessment of the exposure (type, source HIV status and viral load if known, condom use, presence of blood) and of the exposed person’s risk profile.

Follow-up HIV testing is essential because PEP is not 100% effective and because a negative baseline test does not exclude an exposure that occurred just before the PEP episode. Standard practice is repeat HIV testing at 4 to 6 weeks and at 3 months after exposure; some guidelines in addition include a 6-month test, historically because of the window period of older antibody assays and in cases of hepatitis C co-exposure. With modern antigen/antibody combination tests, a negative result at 3 months is generally considered conclusive for HIV in most settings. **[Marked for verification of specific guideline intervals.]**

8. Adherence, Adverse Effects, and Interactions

Adherence is critical. PEP is a 28-day course, and incomplete adherence has been associated with seroconversion despite what was initially adequate initiation. Real-world completion rates are often lower than ideal, particularly for nPEP, where side effects and the logistical burden of a month of medication lead many people to stop early. Counseling, follow-up, and management of side effects materially affect success.

Common adverse effects include nausea, diarrhea, headache, fatigue, and abdominal discomfort; dolutegravir is in addition associated with insomnia and, in a minority, neuropsychiatric symptoms. Serious toxicity is uncommon with modern regimens. Important interactions include the requirement to separate dolutegravir from polyvalent cation supplements — calcium, iron, antacids, and some laxatives — by several hours, and interactions between boosted protease inhibitors and a long list of medications. Pregnancy status may influence the choice of third agent. **[Marked for verification of specific interaction intervals.]**

9. PEP, PrEP, and Doxy-PEP: Distinctions and Limits

Three closely related terms are frequently confused and should be kept distinct:

• PEP is post-exposure, emergency, time-limited (28 days), and initiated after a specific event. It is not a routine prevention strategy.
• PrEP (pre-exposure prophylaxis) is ongoing antiretroviral use before and during periods of risk, taken continuously or on demand by an HIV-negative person. It is the appropriate long-term strategy for people with recurring exposure risk; PEP should not be used repeatedly as a substitute for PrEP.
• Doxy-PEP is something entirely different: a single 200 mg dose of doxycycline taken within 72 hours (ideally 24 hours) after condomless sex to reduce the risk of bacterial sexually transmitted infections — syphilis, chlamydia, and gonorrhea. Doxycycline has no activity against HIV. Doxy-PEP must never be presented as HIV prevention.

The limitations of HIV PEP are equally important to communicate. PEP does not protect against other STIs, is not 100% effective even when used correctly, and depends critically on timing and adherence. It does not prevent pregnancy or other consequences of the exposure. It requires reliable access to care, medication, and follow-up testing, and it carries cost and potential social stigma. For all these reasons, PEP complements — but does not replace — condom use, PrEP, harm-reduction services, and access to clean injection equipment.

10. Conclusion

HIV post-exposure prophylaxis is a well-established component of the HIV prevention toolkit, but its evidence base is uneven and this should be communicated honestly. A 28-day, three-drug regimen started within 72 hours — and ideally within a day — can abort infection by blocking early viral amplification before the latent reservoir is established. The strongest human evidence comes from the occupational setting, where the 1997 case-control study of zidovudine in healthcare workers demonstrated roughly an 81% reduction in transmission; non-occupational PEP, while widely recommended and biologically sound, rests on indirect and observational evidence rather than randomized trials. The preferred modern regimen is TDF/FTC or TAF/FTC plus dolutegravir.

Success depends on speed, adherence, and follow-up HIV testing at approximately 4 to 6 weeks and 3 months. PEP must be distinguished from PrEP, which is the appropriate strategy for ongoing risk, and from Doxy-PEP, which targets bacterial STIs and has no effect on HIV. PEP is an emergency intervention, not a routine prevention method — but used correctly and promptly, it can prevent a lifelong infection in an individual who has just been exposed.

Sources and Key Research Centers

1. U.S. Centers for Disease Control and Prevention (CDC), Division of HIV Prevention — Publishes U.S. guidelines for non-occupational and occupational HIV post-exposure prophylaxis, including recommended regimens and follow-up testing schedules.
2. World Health Organization (WHO) — Issues global guidance on HIV PEP, including for occupational and non-occupational exposure and for survivors of sexual violence.
3. National Institute of Allergy and Infectious Diseases (NIAID), NIH — Funds basic and clinical research on early HIV transmission and prophylaxis, including animal models of mucosal exposure.
4. The New England Journal of Medicine — Published the foundational occupational PEP case-control study: Cardo, D. M., et al. «A case-control study of HIV seroconversion in health care workers after percutaneous exposure.» NEJM, 1997. **[Citation details to be verified.]**
5. U.S. Food and Drug Administration (FDA) — Approves the antiretroviral agents used in PEP regimens (tenofovir, emtricitabine, dolutegravir, raltegravir) and their labeling, including interaction warnings.
6. New York State Department of Health AIDS Institute — HIV Clinical Guidelines Program — Issues detailed, frequently updated nPEP and occupational PEP guidelines used widely as a clinical reference.
7. ClinicalTrials.gov (U.S. National Library of Medicine) — Registry of studies relevant to PEP; search terms: post-exposure prophylaxis, HIV, nPEP, tenofovir, dolutegravir.
8. International AIDS Society (IAS) — Professional society disseminating HIV prevention and treatment guidance, including PEP in the broader prevention continuum.
9. Joint United Nations Programme on HIV/AIDS (UNAIDS) — Provides global epidemiological context for prevention interventions such as PEP.